Summary & Overview
HCPCS J3299: Injection, triamcinolone acetonide (Xipere), 1 mg
HCPCS Level II code J3299 denotes the administration of triamcinolone acetonide (Xipere), 1 mg, a corticosteroid formulation used in ophthalmic procedures such as intravitreal or periocular injection. This code is relevant nationally for clinicians, billers, and payers because it identifies a specific, often high-cost therapeutic agent tied to retinal and ocular inflammatory conditions. Accurate coding influences medical record clarity, payer adjudication, and pharmacy and supply management.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise clinical context for the product and its common sites of service, alongside practical billing considerations typically addressed in payer policies. The publication covers benchmarks and reimbursement baselines where available, prior authorization and medical necessity policy themes commonly seen with specialty ophthalmic injectables, and related coding and billing practices that affect claim acceptance.
The executive summary prepares readers to review payer-specific coverage approaches, common modifier usage, and operational impacts on outpatient ophthalmology workflows. Data not available in the input will be noted in detailed sections.
Billing Code Overview
HCPCS Level II code J3299 describes an injection of triamcinolone acetonide (Xipere), 1 mg. This code represents a single-unit drug administration for an intravitreal or periocular corticosteroid formulation used in ophthalmic care.
Service Type: Drug administration, intravitreal/periocular corticosteroid injection
Typical Site of Service: Outpatient ophthalmology clinic or ambulatory surgery center
Clinical & Coding Specifications
Clinical Context
A typical adult patient presents to an ophthalmology clinic with symptomatic macular edema related to branch retinal vein occlusion. The patient reports decreased central vision and metamorphopsia over several weeks. After clinical examination, optical coherence tomography confirms cystoid macular edema with fluid involving the fovea. The treating retinal specialist determines that an intravitreal sustained‑release triamcinolone acetonide implant (J3299 — triamcinolone acetonide (XIPERE), 1 mg) is appropriate. The clinic obtains informed consent, documents indication, and screens for contraindications (active ocular infection, uncontrolled glaucoma). On the day of service, the patient is prepped in a procedure room or minor procedure suite within the ophthalmology clinic or ambulatory surgery center. Topical anesthetic and povidone‑iodine antisepsis are applied; sterile technique and eyelid speculum are used. The implant is injected intravitreally using manufacturer instructions. The provider documents lot number and quantity administered, any procedural difficulty, and observed immediate complications. Post‑procedure instructions are provided, intraocular pressure is measured before discharge, and a follow‑up visit is scheduled to monitor efficacy and intraocular pressure. Billing uses HCPCS Level II code J3299 for the drug; associated evaluation and management, injection, or imaging services are billed separately per payer rules.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|